Sunvozertinib (Zegfrovy): an oral EGFR inhibitor that irreversibly targets exon20ins in NSCLC.
APA
Niu X, Zhao W, Yu B (2025). Sunvozertinib (Zegfrovy): an oral EGFR inhibitor that irreversibly targets exon20ins in NSCLC.. Trends in pharmacological sciences, 46(12), 1269-1270. https://doi.org/10.1016/j.tips.2025.10.009
MLA
Niu X, et al.. "Sunvozertinib (Zegfrovy): an oral EGFR inhibitor that irreversibly targets exon20ins in NSCLC.." Trends in pharmacological sciences, vol. 46, no. 12, 2025, pp. 1269-1270.
PMID
41224579
같은 제1저자의 인용 많은 논문 (5)
- Discovery of potent TNIK inhibitors containing a 1H-pyrrolo[2,3-b]pyridine scaffold as promising therapeutics for colorectal cancer.
- Anemoside B4 alleviates colitis-associated colon cancer progression via Wnt/β-catenin signaling pathway.
- Using gene methylation detection in bronchoscopic samples combined with morphology-based pathology for lung cancer diagnosis.
- LILRB2 inhibition by blocking antibody ES009 reprograms immunosuppressive myeloid cells and enhances T-cell-mediated tumor immunity.
- Retraction Note: Integration of bioinformatics and cellular experiments unveils the role of SYT12 in gastric cancer.